Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Gomez

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Journal of Pediatric Endocrinology & Metabolism : JPEM|September 14, 2017
Individualised growth response optimisation (iGRO) tool: an accessible and easy-to-use growth prediction system to enable treatment optimisation for children treated with growth hormoneJane Loftus, Anders Lindberg, Ferah Aydin, et al.
Endocrine|December 28, 2014
Pregnancy in acromegaly patients treated with pegvisomantA J van der Lely, Roy Gomez, Joseph F Heissler, et al.
Journal of Neuromuscular Diseases|February 20, 2025
Optimizing DMD management in Asia: Current challenges and future directionsWen-Chin Weng, Sophelia H S Chan, Roy Gomez, et al.
Hormone Research in Paediatrics|April 13, 2022
Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 StudyReiko Horikawa, Toshiaki Tanaka, Yukihiro Hasegawa, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|June 25, 2019
Adult growth hormone deficiency in CEE region: Heterogeneity of the patient pathwayIlan Shimon, Corin Badiu, Artur Bossowski, et al.
Endocrine|November 27, 2018
Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudyThierry Brue, Anders Lindberg, Aart Jan van der Lely, et al.
Endocrine Journal|November 3, 2025
Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 studyReiko Horikawa, Toshiaki Tanaka, Yukihiro Hasegawa, et al.
The Journal of Clinical Endocrinology and Metabolism|April 3, 2022
Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated PatientsGudmundur Johannsson, Philippe Touraine, Ulla Feldt-Rasmussen, et al.
Endocrine Connections|January 10, 2024
Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysisAntonella Giampietro, Sabrina Chiloiro, Claudio Urbani, et al.
The Journal of Clinical Endocrinology and Metabolism|February 25, 2012
Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDYA J van der Lely, Beverly M K Biller, Thierry Brue, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Journal of Pediatric Endocrinology & Metabolism : JPEM|September 14, 2017
Individualised growth response optimisation (iGRO) tool: an accessible and easy-to-use growth prediction system to enable treatment optimisation for children treated with growth hormoneJane Loftus, Anders Lindberg, Ferah Aydin, et al.
Endocrine|December 28, 2014
Pregnancy in acromegaly patients treated with pegvisomantA J van der Lely, Roy Gomez, Joseph F Heissler, et al.
Journal of Neuromuscular Diseases|February 20, 2025
Optimizing DMD management in Asia: Current challenges and future directionsWen-Chin Weng, Sophelia H S Chan, Roy Gomez, et al.
Hormone Research in Paediatrics|April 13, 2022
Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 StudyReiko Horikawa, Toshiaki Tanaka, Yukihiro Hasegawa, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|June 25, 2019
Adult growth hormone deficiency in CEE region: Heterogeneity of the patient pathwayIlan Shimon, Corin Badiu, Artur Bossowski, et al.
Endocrine|November 27, 2018
Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudyThierry Brue, Anders Lindberg, Aart Jan van der Lely, et al.
Endocrine Journal|November 3, 2025
Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 studyReiko Horikawa, Toshiaki Tanaka, Yukihiro Hasegawa, et al.
The Journal of Clinical Endocrinology and Metabolism|April 3, 2022
Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated PatientsGudmundur Johannsson, Philippe Touraine, Ulla Feldt-Rasmussen, et al.
Endocrine Connections|January 10, 2024
Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysisAntonella Giampietro, Sabrina Chiloiro, Claudio Urbani, et al.
The Journal of Clinical Endocrinology and Metabolism|February 25, 2012
Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDYA J van der Lely, Beverly M K Biller, Thierry Brue, et al.
Pageof 3